Biosimilar Market Forecast to Touch more than US$ 13.50 Billion By 2022

New York, December 26, 2018: The scope of the report includes a detailed study of global and regional markets on Biosimilar Market with the reasons given for variations in the growth of the industry in certain regions.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Sandoz International GmbH (Germany), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Samsung Bioepis (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion, Inc. (South Korea), and Biocon Ltd. (India). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

You Can Find Full Report:

A biosimilar is a biologic remedial item which is right around an indistinguishable duplex of a unique item that is made by an alternate company. Biosimilars are formally affirmed variants of unique “trailblazer” items, and can be fabricated when the first item’s patent lapses or gets due. Biosimilars are created in living cells with a multi-step procedure. They should be taken care of and controlled under precisely checked conditions. Biosimilars are utilized to forestall, treat, analyze, or cure an assortment of genuine and ceaseless sicknesses including malignancy, unending kidney illness, immune system issue, and irresistible maladies. The biosimilar market is fragmented on the premise of item, assembling sort, and application. Research and development in biosimilar markets and new signs and patent expiry of biologic items has opened globally a new gate of chances for players in the biosimilar market.

This report provides:

1) An overview of the global market for Biosimilar Market and related technologies.
2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2020.
3) Identifications of new market opportunities and targeted promotional plans for Biosimilar Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.

The Biosimilar Market is expected to exceed more than US$ 13.50 Billion by 2022 at a CAGR of 26.3% in the given forecast period.

The Biosimilar Market has been segmented as below: (Accordingly)

The Biosimilar Market is Segmented on the lines of Manufacturing Type Analysis, Application Analysis, Product Analysis and Regional Analysis. By Manufacturing Type Analysis this market is segmented on the basis of In-house Manufacturing and Contract Manufacturing Organizations. By Application Analysis this market is segmented on the basis of Oncology, Blood Disorders, Chronic & Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases and Other Applications.

By Product Analysis this market is segmented on the basis of Recombinant Non-Glycosylated Proteins its covers Insulin, Recombinant Human Growth Hormones, Granulocyte Colony-stimulating Factor and Interferons. Recombinant Glycosylated Proteins its covers Erythropoietin, Monoclonal Antibodies and Follitropin. And Recombinant Peptides its covers Glucagon and Calcitonin. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

Request Sample Report:

Table of Contents


2 Research Methodology

2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Biosimilars Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Biosimilars Market Breakdown & Data Triangulation
2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Biosimilars Market, By Type of Product

7 Biosimilars Market, By Type of Manufacturing

8 Biosimilars Market, By Application

9 Biosimilars Market, By Region

10 Competitive Landscape

11 Company Profiles

11.1 Introduction
11.2 Pfizer Inc.
11.3 Sandoz International GmbH (A Division of Novartis International AG)
11.4 Teva Pharmaceutical Industries Ltd.
11.5 F. Hoffmann-La Roche Ltd.
11.6 Amgen Inc.
11.7 Biocon Ltd.
11.8 Dr. Reddy’s Laboratories
11.9 Celltrion Inc.
11.10 Mylan Inc.
11.11 Samsung Bioepis

Other Related Market Research Reports:

Bio Bank Market Size is Projected to be Around US$ 760 Million By 2022

Biomarkers Market Share will Increase US$ 60 Billion By 2023

Bleeding Disorders Treatment Market Size is Projected to be Around US$ 14.50 Billion By 2022

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay


Phone: +1-855-984-1862

Country: United States


Leave a Reply

Your email address will not be published. Required fields are marked *